ArticleBMC nephrology2026
In vivo and molecular docking investigation of the novel anti-inflammatory and mitochondrial mechanisms underlying the renoprotective effects of resmetirom and curcumin in gentamicin-induced renal toxicity in rats.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGentamicin (GS) is a potent aminoglycoside antibiotic whose clinical use is limited by nephrotoxicity associated with oxidative stress, mitochondrial dysfunction, and inflammation. This study aimed to explore the renoprotective mechanisms of resmetirom (RES) and curcumin (CUR) against GS-induced renal injury in rats, emphasizing anti-inflammatory and mitochondrial pathways and supporting findings through molecular docking.
methodsTwenty-four adult male Wistar rats were randomly allocated into four groups (n = 6): control, GS (100 mg/kg, i.p.), GS + CUR (200 mg/kg, oral), and GS + RES (3 mg/kg, oral). Treatments were administered for seven days. Serum renal biomarkers (urea, creatinine) and tissue oxidative stress markers (MDA, NO, GSH) were quantified using spectrophotometric methods. Specific kidney damage indicators for kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were evaluated. Gene expressions of dynamin-related protein 1 (DRP1) and AKT Serine/Threonine Kinase 1 (AKT1) were analyzed by quantitative RT-PCR, while mammalian target of rapamycin (mTOR) and forkhead box protein O1 (FOXO1) protein expression were assessed immunohistochemically. Histopathological and ultrastructural evaluations were conducted using light and electron microscopy. Molecular docking was performed using AutoDock Vina to assess binding affinities of CUR and RES with AKT1, DRP1, FOXO1, and mTOR.
resultsGS administration significantly elevated serum urea and creatinine and increased renal MDA levels while decreasing NO and GSH. These alterations were markedly attenuated by CUR and RES, with RES showing superior improvement in renal function and oxidative balance. qPCR analysis revealed significant GS-induced upregulation of AKT1 and DRP1, which was normalized by both CUR and RES. Immunohistochemistry demonstrated downregulation of mTOR and FOXO1 following GS exposure, with substantial restoration after CUR and RES treatments. Histopathological and ultrastructural analyses confirmed the protective effects of both compounds, showing preserved glomerular and tubular integrity.
conclusionResmetirom and CUR showed significant renoprotective benefits against GS-induced nephrotoxicity by alleviating oxidative stress, modulating mitochondrial dynamics, and restoring cellular signaling pathways involving AKT1, DRP1, mTOR, and FOXO1. The molecular docking results corroborate their direct interactions with these targets, highlighting RES as a promising therapeutic agent for nephroprotection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.